

AMENDMENTS TO THE CLAIMS

Claims 1-2 (Canceled).

Claim 3 (Previously Presented): An immunogenic composition comprising as an immunogen a long synthetic or recombinant peptide consisting of a MSP-3c peptide (SEQ ID No: 13), or a MSP-3d peptide (SEQ ID No. 14) and combinations of said peptides.

Claim 4 (Previously Presented): A vaccine against malaria comprising the long synthetic or recombinant peptide of Claim 3 and a pharmaceutically acceptable carrier.

Claim 5 (Previously Presented): The immunogenic composition of claim 3, wherein said long synthetic or recombinant peptide further consists of a MSP-3a peptide (SEQ ID No: 11).

Claim 6 (Previously Presented): The immunogenic composition of claim 3, which is formulated for subcutaneous injection.

Claim 7 (Currently Amended): The immunogenic composition of claim 6, comprising ~~between 3 µg and to~~ 100 µg of a long synthetic peptide per injection dose.

Claim 8 (Previously Presented): The immunogenic composition of claim 3, further comprising Alum, or an oil/surfactant adjuvant wherein the oil phase is selected from a non-metabolizable mineral oil, a metabolizable mineral oil or a mixture of the two, as an adjuvant.

Claim 9 (Previously Presented): The vaccine of claim 4, wherein said pharmaceutically acceptable carrier comprises Alum or an oil/surfactant adjuvant wherein the

oil phase is selected from a non-metabolizable mineral oil, a metabolizable mineral oil or a mixture of the two.

Claims 10-24 (Canceled).

Claim 25 (Previously Presented): The vaccine of claim 4, wherein said long synthetic or recombinant peptide further consists of SEQ ID No: 11.

Claim 26 (Previously Presented): The vaccine of claim 4, which is formulated for subcutaneous injection.

Claim 27 (Currently Amended): The vaccine of claim 26, comprising ~~between 3 µg and to 100 µg~~ of a long synthetic peptide per injection dose.

Claim 28 (Currently Amended): An immunogenic composition comprising as an immunogen a long synthetic or recombinant peptide consisting of mixtures combinations of peptides of a MSP-3b peptide (SEQ ID No: 12), a MSP-3c peptide (SEQ ID No: 13) and a MSP-3d peptide (SEQ ID No: 14).

Claim 29 (Currently Amended): A vaccine against malaria comprising a long synthetic or recombinant peptide consisting of mixtures combinations of peptides of a MSP-3b peptide (SEQ ID No: 12), a MSP-3c peptide (SEQ ID No: 13) and a MSP-3d peptide (SEQ ID No: 14) and a pharmaceutically acceptable carrier.

SUPPORT FOR THE AMENDMENTS

Claims 1, 2, and 10-24 were previously canceled.

Claims 7 and 27-29 have been amended.

Support for the amendment of Claims 7 and 27 is provided by Example 6 on pages 32-35 of the specification. Support for the amendment of Claims 28-29 is provided by the corresponding claims as previously presented, as well as the originally filed claims.

No new matter has been added by the present amendments.